159992 创新药
已收盘 08-16 15:00:00
资讯
新帖
简况
8月16日普利制药涨20.00%，天弘恒生沪深港创新药精选50ETF发起联接A基金重仓该股
证券之星 · 08-16 16:14
8月16日普利制药涨20.00%，天弘恒生沪深港创新药精选50ETF发起联接A基金重仓该股
8月16日亚太药业涨停分析：幽门螺杆菌概念，化学原料药，创新药概念热股
证券之星 · 08-16 15:26
8月16日亚太药业涨停分析：幽门螺杆菌概念，化学原料药，创新药概念热股
8月16日海辰药业涨停分析：化学原料药，新冠药物，创新药概念热股
证券之星 · 08-16 15:26
8月16日海辰药业涨停分析：化学原料药，新冠药物，创新药概念热股
华东医药(000963.SZ)与韩国IMB强强联手！医药老大哥再添两款自免创新药
智通财经 · 08-16 08:30
华东医药(000963.SZ)与韩国IMB强强联手！医药老大哥再添两款自免创新药
益诺思：拟首发募资16亿元投建非临床创新药物综合评价平台扩建等项目 8月23日申购
中证网 · 08-15 18:06
益诺思：拟首发募资16亿元投建非临床创新药物综合评价平台扩建等项目 8月23日申购
美银：上调中国生物制药目标价至3.8港元 创新药渠道开发已步入正轨
金融界 · 08-15 15:32
美银：上调中国生物制药目标价至3.8港元 创新药渠道开发已步入正轨
康方生物(09926.HK)创新药“依达方”获纳入优先审评
阿斯达克财经 · 08-15 11:40
康方生物(09926.HK)创新药“依达方”获纳入优先审评
创新药概念普升 百济神州(06160)涨3.14% 机构指出海授权和重磅创新将是行业投资催化剂
金吾财讯 · 08-15 10:58
创新药概念普升 百济神州(06160)涨3.14% 机构指出海授权和重磅创新将是行业投资催化剂
“创新药”热度持续高涨，重大利好落地！益诺思科创板IPO
中宏网官微 · 08-15 10:07
“创新药”热度持续高涨，重大利好落地！益诺思科创板IPO
【方正医药】华纳药厂(688799)：布局抑郁症原创新药与濒危药材人工替代，打造原料药制剂一体化综合平台
方正证券研究 · 08-15 08:30
【方正医药】华纳药厂(688799)：布局抑郁症原创新药与濒危药材人工替代，打造原料药制剂一体化综合平台
【金十数据整理：亚盘需要关注的个股新闻事件（8月15日）】1. 世卫组织宣布猴痘构成“国际关注的突发公共卫生事件”。2. TCL华星回应面板厂国庆停产两周传闻称 还没发正式通知。
美港电讯 · 08-15 07:59
【金十数据整理：亚盘需要关注的个股新闻事件（8月15日）】1. 世卫组织宣布猴痘构成“国际关注的突发公共卫生事件”。2. TCL华星回应面板厂国庆停产两周传闻称 还没发正式通知。
广生堂最新公告：公司乙肝治疗创新药GST-HG141存在结果不及预期甚至临床研究失败的风险
证券之星 · 08-14
广生堂最新公告：公司乙肝治疗创新药GST-HG141存在结果不及预期甚至临床研究失败的风险
美诺华(603538.SH)：能够承接创新药相关CDMO业务
格隆汇资讯 · 08-14
美诺华(603538.SH)：能够承接创新药相关CDMO业务
IPO观察|华昊中天二度递表港交所，聚焦肿瘤创新药开发，尚未实现盈利
红星资本局 · 08-14
IPO观察|华昊中天二度递表港交所，聚焦肿瘤创新药开发，尚未实现盈利
北京又一创新药企冲刺上市
北京日报客户端 · 08-14
北京又一创新药企冲刺上市
荣昌生物(09995.HK)创新药泰它西普Ⅲ期临床研究达主要终点
阿斯达克财经 · 08-13
荣昌生物(09995.HK)创新药泰它西普Ⅲ期临床研究达主要终点
治疗重症肌无力的创新药Ⅲ期临床效果良好！荣昌生物回应：中报后可能会举行相关说明会
南方财经网 · 08-13
治疗重症肌无力的创新药Ⅲ期临床效果良好！荣昌生物回应：中报后可能会举行相关说明会
广生堂：公司乙肝治疗创新药 GST-HG141已获得II 期临床试验研究初步结果且达到预设目标
证券之星 · 08-13
广生堂：公司乙肝治疗创新药 GST-HG141已获得II 期临床试验研究初步结果且达到预设目标
瑞联新材：公司主要产品包括OLED材料、单体液晶、创新药中间体及其他电子化学品材料
每日经济新闻 · 08-13
瑞联新材：公司主要产品包括OLED材料、单体液晶、创新药中间体及其他电子化学品材料
创新药概念盘中跳水，百利天恒-U平盘
自选股智能写手 · 08-13
创新药概念盘中跳水，百利天恒-U平盘
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.632,"timestamp":1723791831000,"preClose":0.627,"halted":0,"volume":286080600,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","marketStatusCode":5,"change":0.005,"latestTime":"08-16 15:00:00","open":0.626,"high":0.634,"low":0.621,"amount":180000000,"amplitude":0.0207,"askPrice":0.632,"askSize":2228,"bidPrice":0.631,"bidSize":23984,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724031000000},"adr":0,"adjPreClose":0.627,"symbolType":"fund","openAndCloseTimeList":[[1723771800000,1723779000000],[1723784400000,1723791600000]],"highLimit":0.69,"lowLimit":0.564,"ibTradeSell":false,"ibTradeBuySell":true,"pbRate":0,"committee":-0.265411,"marketValue":0,"floatMarketCap":0,"changeRate":0.008,"turnoverRate":0,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-08-19。","discountRate":"0.00%","netWorth":"0.000"},"requestUrl":"/m/hq/s/159992","defaultTab":"news","newsList":[{"id":"2459262934","title":"8月16日普利制药涨20.00%，天弘恒生沪深港创新药精选50ETF发起联接A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2459262934","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459262934?lang=zh_cn&edition=full","pubTime":"2024-08-16 16:14","pubTimestamp":1723796074,"startTime":"0","endTime":"0","summary":"证券之星消息，8月16日普利制药涨20.00%，收盘报10.44元，换手率18.92%，成交量64.0万手，成交额6.08亿元。根据2024基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为天弘恒生沪深港创新药精选50ETF发起联接A。天弘恒生沪深港创新药精选50ETF发起联接A目前规模为0.21亿元，最新净值0.7311，较上一交易日上涨0.79%，近一年下跌21.65%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081600031878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300630","159982","399300","BK0239","BK1161","BK1574","159992","06978"],"gpt_icon":0},{"id":"2459696602","title":"8月16日亚太药业涨停分析：幽门螺杆菌概念，化学原料药，创新药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2459696602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459696602?lang=zh_cn&edition=full","pubTime":"2024-08-16 15:26","pubTimestamp":1723793190,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业8月16日涨停收盘，收盘价3.06元。该股于10点59分涨停，未打开涨停，截止收盘封单资金为1794.48万元，占其流通市值0.96%。近5日资金流向一览见下表：该股为幽门螺杆菌概念，化学原料药，创新药概念热股，当日幽门螺杆菌概念概念上涨1.93%，化学原料药概念上涨1.65%，创新药概念上涨0.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081600026304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK1161","BK1574","002370","06978","159992","BK0239"],"gpt_icon":0},{"id":"2459426995","title":"8月16日海辰药业涨停分析：化学原料药，新冠药物，创新药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2459426995","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459426995?lang=zh_cn&edition=full","pubTime":"2024-08-16 15:26","pubTimestamp":1723793175,"startTime":"0","endTime":"0","summary":"证券之星消息，海辰药业8月16日涨停收盘，收盘价23.54元。该股于13点35分涨停，未打开涨停，截止收盘封单资金为4625.26万元，占其流通市值2.39%。8月16日的资金流向数据方面，主力资金净流出5461.45万元，占总成交额10.54%，游资资金净流入2231.31万元，占总成交额4.31%，散户资金净流入3230.14万元，占总成交额6.23%。近5日资金流向一览见下表：该股为化学原料药，新冠药物，创新药概念热股，当日化学原料药概念上涨1.65%，新冠药物概念上涨1.42%，创新药概念上涨0.93%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081600026289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","06978","BK0239","300584","159992","BK1574"],"gpt_icon":0},{"id":"2459238696","title":"华东医药(000963.SZ)与韩国IMB强强联手！医药老大哥再添两款自免创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2459238696","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459238696?lang=zh_cn&edition=full","pubTime":"2024-08-16 08:30","pubTimestamp":1723768230,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2024年8月15日，华东医药发布公告称，其全资子公司中美华东与韩国IMBiologics corp.签订了产品独家许可协议，获得IMB两款自身免疫领域的全球创新产品IMB-101及IMB-102在包含中国在内的 37个亚洲国家的独家许可，包括开发、注册、生产及商业化权益。公告显示，本次交易涉及IMB拥有的2款自身免疫领域全球创新生物制剂。华东医药表示，未来将继续以临床需求和患者为先，与国内外优秀的企","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1165107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","000963","06978","BK0132","BK0175","LU1969619763.USD","BK0196","BK1574","09939","BK1161","LU2328871848.SGD","BK0183","159992","BK0188","159938","BK0209","BK1515"],"gpt_icon":0},{"id":"2459449217","title":"益诺思：拟首发募资16亿元投建非临床创新药物综合评价平台扩建等项目 8月23日申购","url":"https://stock-news.laohu8.com/highlight/detail?id=2459449217","media":"中证网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459449217?lang=zh_cn&edition=full","pubTime":"2024-08-15 18:06","pubTimestamp":1723716360,"startTime":"0","endTime":"0","summary":"公司拟在科创板公开发行3524.49万股，募集资金16.02亿元，投建益诺思总部及创新转化中心项目、高品质非临床创新药物综合评价平台扩建项目，并补充流动资金。本次发行初步询价日期8月20日，申购日期8月23日。与此同时，公司将逐步增强弱势业务，并充分发挥核心业务导流效应，抢占新增业务市场份额，综合实现营业收入快速增长。分产品来看，非临床、临床2023年毛利率分别为44.69%、14.95%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-08-15/doc-incitnse6610664.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-08-15/doc-incitnse6610664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688710","BK1161","159992","06978","BK1574"],"gpt_icon":0},{"id":"2459160954","title":"美银：上调中国生物制药目标价至3.8港元 创新药渠道开发已步入正轨","url":"https://stock-news.laohu8.com/highlight/detail?id=2459160954","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459160954?lang=zh_cn&edition=full","pubTime":"2024-08-15 15:32","pubTimestamp":1723707170,"startTime":"0","endTime":"0","summary":"美银证券发表报告指出，中国生物制药上半年收入按年增长11.1%至159亿元，毛利升11.5%至130亿元，毛利率由去年上半年的81.8%微升至今年上半年的82.1%。纯利升近1.4倍至30亿元。如剔除已终止 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20240815/c660819574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2459460895","title":"康方生物(09926.HK)创新药“依达方”获纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2459460895","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459460895?lang=zh_cn&edition=full","pubTime":"2024-08-15 11:40","pubTimestamp":1723693200,"startTime":"0","endTime":"0","summary":"康方生物(09926.HK) 公布，中国国家药品监督管理局药品审评中心昨日(14日)公示，公司旗下创新药依沃西单抗注射液“依达方”(PD-1/VEGF双抗，AK112)，被纳入优先审评品种名单，该适应症的上市申请基于HARMONi-2(AK112-303)研究，已于上月底获受理。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-14 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1371842/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1720050803.USD","LU0348784397.USD","IE00BPRC5H50.USD","LU0417516571.SGD","LU0348783233.USD","IE00B5MMRT66.SGD","BK1161","LU1794554557.SGD","159992","BK1574","LU2488822045.USD","06978","09926","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2459464598","title":"创新药概念普升 百济神州(06160)涨3.14% 机构指出海授权和重磅创新将是行业投资催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2459464598","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459464598?lang=zh_cn&edition=full","pubTime":"2024-08-15 10:58","pubTimestamp":1723690691,"startTime":"0","endTime":"0","summary":"国金证券表示，从已披露中报看，创新药企业整体业绩向好趋势明显，百济神州、和黄药业、信达生物等部分药企核心品种销售表现亮丽。上半年以来，创新药鼓励政策陆续落地，此时叠加业绩改善，同时考虑海外流动性变化趋势，该行认为创新药板块有望继续得到市场重视，出海授权和重磅创新将是最大的投资催化剂。","market":"other","thumbnail":"https://static.szfiu.com/news/20200908/ZDU2M2ViYzhjNGM0OGI0Yjc0M2IyM2I2YWYxMTE5OTk0MjE4MDAxMQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/ZDU2M2ViYzhjNGM0OGI0Yjc0M2IyM2I2YWYxMTE5OTk0MjE4MDAxMQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1942341","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK0239","LU0588546209.SGD","BK1161","159992","BK1574","BK1589","LU0307460666.USD","LU1969619763.USD","09995","06978","01801","BK4526","LU2328871848.SGD","BK1576","LU1720050803.USD","688235","IE00BPRC5H50.USD","LU0348783233.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","LU2488822045.USD","BGNE","BK4585","BK4505","IE00B543WZ88.USD","BK4504","BK1141","LU0417516571.SGD","BK1588","BK4548","BK1587","BK1500","BK4535","09969","06160","09926","BK1583","00013","BK4588","LU0348784397.USD","BK1191","01521","02162"],"gpt_icon":0},{"id":"2459321466","title":"“创新药”热度持续高涨，重大利好落地！益诺思科创板IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2459321466","media":"中宏网官微","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459321466?lang=zh_cn&edition=full","pubTime":"2024-08-15 10:07","pubTimestamp":1723687620,"startTime":"0","endTime":"0","summary":"使创新药企业备受鼓舞。会议指出，发展创新药关系医药产业发展，关系人民健康福祉。 值得注意的是，今年以来，一系列针对创新药产业及高质量发展的利好政策密集出台，彰显了国家对这一领域的高度重视与支持。上海益诺思生物技术股份有限公司于2024年5月15日成功在科创板获得证监会的IPO注册后，于2024年8月15日公告招股意向书，进入发行上市阶段。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-08-15/doc-incisvui8506036.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-08-15/doc-incisvui8506036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159992","06978","159982","BK1161","688710"],"gpt_icon":0},{"id":"2459445109","title":"【方正医药】华纳药厂(688799)：布局抑郁症原创新药与濒危药材人工替代，打造原料药制剂一体化综合平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2459445109","media":"方正证券研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459445109?lang=zh_cn&edition=full","pubTime":"2024-08-15 08:30","pubTimestamp":1723681840,"startTime":"0","endTime":"0","summary":"本文来自方正证券研究所于2024年8月14日发布的报告《华纳药厂：布局抑郁症原创新药与濒危药材人工替代，打造原料药制剂一体化综合平台》，欲了解具体内容，请阅读报告原文。原创抗抑郁新药有望成为潜在BIC品种，分享百亿级市场空间。独家布局濒危动物药材人工替代品，抢占数十亿产业空间先机。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408150842259f2be50b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408150842259f2be50b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159938","159992","BK0239","688799"],"gpt_icon":0},{"id":"2459455752","title":"【金十数据整理：亚盘需要关注的个股新闻事件（8月15日）】1. 世卫组织宣布猴痘构成“国际关注的突发公共卫生事件”。2. TCL华星回应面板厂国庆停产两周传闻称 还没发正式通知。","url":"https://stock-news.laohu8.com/highlight/detail?id=2459455752","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459455752?lang=zh_cn&edition=full","pubTime":"2024-08-15 07:59","pubTimestamp":1723679957,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["06978","600686","GLD","BK0072","300139","00728","BK0108","CHA","603458","GDX","300067","BK1610","300860","IAU","MGCmain","LU1328615791.USD","159934","BK0026","002999","159992","159831","601107","BK1536","BK0121","GST","LU1242518931.SGD","002241","002738","001314","SGUmain","NUGT","BK0229","SGCmain","01072","518880","DUST","603887","600351","BK0209","BK0096","300436","600875","SG9999001093.SGD","601728","BK0000","BK0228","BK0231","BK0035","GCmain","002505"],"gpt_icon":0},{"id":"2459121326","title":"广生堂最新公告：公司乙肝治疗创新药GST-HG141存在结果不及预期甚至临床研究失败的风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2459121326","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459121326?lang=zh_cn&edition=full","pubTime":"2024-08-14 19:10","pubTimestamp":1723633829,"startTime":"0","endTime":"0","summary":"广生堂发布股票交易异常波动公告，公司乙肝治疗创新药GST-HG141于2019年11月获得国内临床试验许可，目前处于临床II期阶段，已完成临床研究结果数据揭盲。创新药研发周期长，投入大，风险高，容易受到技术、审批、政策等多方面因素的影响，临床研究存在结果不及预期甚至临床研究失败的风险，后续能否获得批准存在不确定性。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081400039293.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","06978","BK0239","300436","BK1161"],"gpt_icon":0},{"id":"2459126157","title":"美诺华(603538.SH)：能够承接创新药相关CDMO业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2459126157","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459126157?lang=zh_cn&edition=full","pubTime":"2024-08-14 18:33","pubTimestamp":1723631630,"startTime":"0","endTime":"0","summary":"格隆汇8月14日丨美诺华(603538.SH)于投资者互动平台表示，公司能够承接创新药相关CDMO业务，公司拥有符合中国以及国际标准的CDMO生产体系及专业的研发团队。公司目前自研制剂为仿制药，公司制剂产品的治疗领域以心血管疾病等慢性疾病为主。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081418335495982262&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081418335495982262&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603538","BK0239","159992"],"gpt_icon":0},{"id":"2459779144","title":"IPO观察|华昊中天二度递表港交所，聚焦肿瘤创新药开发，尚未实现盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2459779144","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459779144?lang=zh_cn&edition=full","pubTime":"2024-08-14 17:03","pubTimestamp":1723626180,"startTime":"0","endTime":"0","summary":"红星资本局注意到，这是华昊中天第二次递表港交所。2022年6月30日，华昊中天递交了科创板上市申请并获得受理；2023年5月23日，公司撤回了科创板上市审核。今年1月29日，该公司首次递表港交所。招股书显示，华昊中天的核心产品优替德隆注射液于2021年获得国家药监局批准上市，用于治疗复发或转移性晚期乳腺癌。业绩上，华昊中天近年来收入稳步增长，但尚未实现盈利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/cj/2024-08-14/doc-incircmc9305652.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/cj/2024-08-14/doc-incircmc9305652.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06978","BK1574","159992"],"gpt_icon":0},{"id":"2459554161","title":"北京又一创新药企冲刺上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2459554161","media":"北京日报客户端","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459554161?lang=zh_cn&edition=full","pubTime":"2024-08-14 05:35","pubTimestamp":1723584900,"startTime":"0","endTime":"0","summary":"本报讯 北京又一家创新药企冲刺上市。记者昨天获悉，北京华昊中天生物医药股份有限公司再次向香港交易所主板提交上市申请。今年1月29日，该公司曾递交过一次招股书。 招股书显示，华昊中天成立于2002年7月，于2021年5月完成股改，是一家合成生物学技术驱动的全球化生物医药公司，致力于开发肿瘤创新药。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-08-14/doc-incipzxu8024545.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-08-14/doc-incipzxu8024545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","06978","BK1161","159992"],"gpt_icon":0},{"id":"2459183027","title":"荣昌生物(09995.HK)创新药泰它西普Ⅲ期临床研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2459183027","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459183027?lang=zh_cn&edition=full","pubTime":"2024-08-13 23:28","pubTimestamp":1723562880,"startTime":"0","endTime":"0","summary":"荣昌生物(09995.HK) 公布，公司自主研发的BLyS/APRIL双靶点融合蛋白创新药泰它西普(RC18，商品名：泰爱)用于治疗全身型重症肌无力的Ⅲ期临床研究，达到方案设计的临床试验主要研究终点。研究发现，相比传统免疫治疗方案，B细胞靶向治疗可显著降低重症肌无力的复发率，且停药率低。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-13 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1371259/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09995","LU1064130708.USD","LU1064131003.USD","688331","LU2148510915.USD","BK0239","159992","BK1161","06978","LU1969619763.USD","LU2328871848.SGD","BK1574","BK1583"],"gpt_icon":0},{"id":"2459092091","title":"治疗重症肌无力的创新药Ⅲ期临床效果良好！荣昌生物回应：中报后可能会举行相关说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2459092091","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459092091?lang=zh_cn&edition=full","pubTime":"2024-08-13 17:54","pubTimestamp":1723542844,"startTime":"0","endTime":"0","summary":"临床研究结果显示，泰它西普可持续有效改善全身型重症肌无力患者的临床症状，显示良好的疗效和安全性。7月24日，荣昌生物发布公告称，董事会对发行方案中的募集资金规模及相关事项进行调整，将拟募资额从不超25.5亿元调整至不超19.53亿元，投向新药研发项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081318065495950361&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081318065495950361&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","688331","09995","LU1064131003.USD","BK0239","LU1064130708.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2459929718","title":"广生堂：公司乙肝治疗创新药 GST-HG141已获得II 期临床试验研究初步结果且达到预设目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2459929718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459929718?lang=zh_cn&edition=full","pubTime":"2024-08-13 17:04","pubTimestamp":1723539864,"startTime":"0","endTime":"0","summary":"通过持续的研发投入，公司实现了创新药获批“0”的突破，抗新冠创新药泰中定项目GST-HG171成功获批上市，为公司的创新能力提升和长期发展奠定了坚实的基础。投资者：公司此前公告，GST-HG141已完成临床II期临床患者入组。广生堂董秘：您好，公司乙肝治疗创新药 GST-HG141已获得II 期临床试验研究初步结果且达到预设目标。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081300033720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK1574","BK1576","BK1583","BK1161","03347","BK0239","159992","300436","06978"],"gpt_icon":0},{"id":"2459664940","title":"瑞联新材：公司主要产品包括OLED材料、单体液晶、创新药中间体及其他电子化学品材料","url":"https://stock-news.laohu8.com/highlight/detail?id=2459664940","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459664940?lang=zh_cn&edition=full","pubTime":"2024-08-13 15:18","pubTimestamp":1723533507,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：贵公司最近有意向与国际食品品牌星球兽合作吗？瑞联新材（688550.SH）8月12日在投资者互动平台表示，公司主要产品包括OLED材料、单体液晶、创新药中间体及其他电子化学品材料，未与您提及的企业进行业务合作。(记者 蔡鼎)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408131519079f2691ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408131519079f2691ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0229","688550","159992"],"gpt_icon":0},{"id":"2459997892","title":"创新药概念盘中跳水，百利天恒-U平盘","url":"https://stock-news.laohu8.com/highlight/detail?id=2459997892","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459997892?lang=zh_cn&edition=full","pubTime":"2024-08-13 09:56","pubTimestamp":1723514179,"startTime":"0","endTime":"0","summary":"08月13日，创新药概念盘中跳水，截至09点56分，创新药概念整体指数下跌1.12%，报717.830点。从个股上来看，该概念的成分股中，百利天恒-U平盘，诺诚健华-U、百花医药跌幅居前。从资金上来看，截止发稿，创新药概念主力净流入为-5.80亿，其中东北制药受到资金热捧，主力净流入5986.58万；拉长时间线来看，该板块近20日主力资金净流入-54.75亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240813095619af972b06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240813095619af972b06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","688506","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"stockEarnings":[{"period":"1week","weight":0.0016},{"period":"1month","weight":0.0064},{"period":"3month","weight":-0.0959},{"period":"6month","weight":-0.0946},{"period":"1year","weight":-0.2217},{"period":"ytd","weight":-0.2339}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0282},{"period":"3month","weight":-0.0871},{"period":"6month","weight":0.0047},{"period":"1year","weight":-0.0899},{"period":"ytd","weight":-0.0321}],"serverTime":1723893929105,"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}